louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05188482: Using Vibroacoustic Therapy in a Patient With Co-infection and COVID-19
Official title: Complex Treatment Using Vibroacoustic Therapy in a Patient With Co-infection and COVID-19: Case Report.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: SARS CoV 2 Infection
Keywords: periprosthetic joint infection
SARS-CoV-2
co-infections
case report.
vibroacoustic therapy
Lead sponsor: Astana Medical University
Sponsor class: OTHER
First posted: 2022-01-12
Enrollment: 1
Sex: MALE
Minimum age (years): 59
Maximum age (years): 59
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 59-year-old man with sepsis as a result of periprosthetic infection against the background of severe SARS-CoV-2-19,

Brief summary: This article describes a case of successful treatment of a 59-year-old man with sepsis as a result of periprosthetic infection against the background of severe SARS-CoV-2-19, who was hospitalized for 59 days, 57 of which were in the intensive care unit. Vibroacoustic pulmonary therapy, the concept of noninvasive ventilation, syndrome therapy, combination antibiotic therapy taking into account the pathogen and antibiotic sensitivity were used in the treatment.

Detailed description: During the pandemic caused by SARS-CoV-2-19, the whole world faced difficulties. Nevertheless, surgeons had to perform surgical treatment for patients who needed immediate help with a confirmed coronavirus infection \[1, 2, 3\].

Periprosthetic joint infection is a severe and undesirable consequence after arthroplasty \[4, 5\]. Patients with coronavirus infection and bacterial infection correlate with an unfavorable outcome \[6, 7, 8\] The effect of vibroacoustic therapy in the treatment of various conditions has not been sufficiently studied \[9, 10\]. This clinical case describes the complex therapy of a patient with a periprosthetic infection on the background of SARS-CoV-2 using a vibroacoustic pulmonary device.

Eligibility criteria: Inclusion Criteria:

* P/F less 300 torr
* COVID-19 Virus Infection

Exclusion Criteria:

* children
* acute stroke
* acute coronary syndrome
* DVT
* implanted pacemaker
* rib fracture
* infection on chest

Primary outcomes:
measure: Change of time spent on ventilation
timeFrame: 1-2 days
Secondary outcomes:
Other outcomes:
Locations:
city: Astana
country: Kazakhstan
facility: NATIONAL CENTER Scientific Center of Traumatology and Orthopedics named after Academician Batpenov N.D.
Study officials:
References:
Clinical trial NCT00546182: Simvastatin Reduces Adiponectin Levels and Insulin Sensitivity
Official title: Phase 4 Study of Simvastatin That Affects Insulin Sensitivity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypercholesterolemia
Keywords: Lipophilic statins
Insulin resistance
hypercholesterolemic patients
Lead sponsor: Gachon University Gil Medical Center
Sponsor class: OTHER
First posted: 2007-10-18
Sex: ALL
Minimum age (years): 25
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Study population: overweight hypercholesterolemic patients

Brief summary: We hypothesized simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients.


Eligibility criteria: Inclusion Criteria:

* Low-density lipoprotein cholesterol levels more than 100 and body mass index more than 23.0

Exclusion Criteria:

* Patients with overt liver disease
* Chronic renal failure
* Hypothyroidism, myopathy
* Uncontrolled diabetes
* Severe hypertension, stroke
* Acute coronary events
* Coronary revascularization within the preceding 3 months, or
* Alcohol abuse.

Primary outcomes:
measure: simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients
Secondary outcomes:
Other outcomes:
Locations:
city: Incheon
country: Korea, Republic of
facility: Gil Medical Center, Gachon University
Study officials:
affiliation: Gachon University Gil Medical Center
name: Kwang K Koh, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999 Mar;126(5):1205-13. doi: 10.1038/sj.bjp.0702397.
Clinical trial NCT02939482: A Study Comparison of Clinical Outcome After Different Rate of Infusion in Caudal Epidural Steroid Injection
Official title: A Prospective Study Comparison of Clinical Outcome After Different Rate Infusion in Caudal Epidural Steroid Injection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spinal Stenosis
Lumbosacral Spondylosis
Radiculopathy
Lead sponsor: Navamindradhiraj University
Sponsor class: OTHER
First posted: 2016-10-20
Enrollment: 112
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effects of different rates of Caudal Epidural Steroid Injection (CESI) on clinical outcomes of the patients.


Eligibility criteria: Inclusion Criteria:

* lumbosacral spinal stenosis with radiculopathy
* no improvement after conservative treatment for 6 weeks

Exclusion Criteria:

* previous CESI or spinal surgery
* skin infection at injection site
* uncontrolled diabetes mellitus
* abnormal coagulogram
* vertebral fracture
* previous history of allergy to steroid or anesthetic agent

Primary outcomes:
measure: Change from baseline Visual Analogue Scale at 2, 6, 12 weeks
timeFrame: 2, 6, 12 weeks
measure: Change from baseline Roland 5-point pain scale at 2, 6, 12 weeks
timeFrame: 2, 6, 12 weeks
measure: Change from baseline Standing tolerance test at 2, 6, 12 weeks
timeFrame: 2, 6, 12 weeks
measure: Change from baseline Walking tolerance test at 2, 6, 12 weeks
timeFrame: 2, 6, 12 weeks
measure: Change from baseline Patient satisfaction scale at 2, 6, 12 weeks
timeFrame: 2, 6, 12 weeks
Secondary outcomes:
measure: Complication of Caudal Epidural Steroid Injection
timeFrame: 2, 6, 12 weeks
Other outcomes:
Locations:
city: Dusit
country: Thailand
facility: Navamindradhiraj University
state: Bangkok
Study officials:
affiliation: Navamindradhiraj University
name: Satit Thiengwittayaporn, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Watts RW, Silagy CA. A meta-analysis on the efficacy of epidural corticosteroids in the treatment of sciatica. Anaesth Intensive Care. 1995 Oct;23(5):564-9. doi: 10.1177/0310057X9502300506.
citation: Botwin KP, Gruber RD, Bouchlas CG, Torres-Ramos FM, Sanelli JT, Freeman ED, Slaten WK, Rao S. Fluoroscopically guided lumbar transformational epidural steroid injections in degenerative lumbar stenosis: an outcome study. Am J Phys Med Rehabil. 2002 Dec;81(12):898-905. doi: 10.1097/00002060-200212000-00003.
citation: Kraiwattanapong C, Wechmongkolgorn S, Chatriyanuyok B, Woratanarat P, Udomsubpayakul U, Chanplakorn P, Keorochana G, Wajanavisit W. Outcomes of fluoroscopically guided lumbar transforaminal epidural steroid injections in degenerative lumbar spondylolisthesis patients. Asian Spine J. 2014 Apr;8(2):119-28. doi: 10.4184/asj.2014.8.2.119. Epub 2014 Apr 8.
Clinical trial NCT03033082: Evaluation of Marital and Sexual Satisfaction of Wives to Erectile Dysfunction Males
Official title: Evaluation of Marital and Sexual Satisfaction of Wives to Erectile Dysfunction Males Using Intra Corporeal Injection (Ici). In Correlation to Personality Profile
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Erectile Dysfunction
Lead sponsor: Adam International Hospital
Sponsor class: OTHER
First posted: 2017-01-26
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Males complaining of erectile dysfunction.

Brief summary: Erectile Dysfunction (ED), previously known as sexual impotence, is defined as the persistent inability to obtain and/or maintain a penile erection that is hard enough for satisfactory sexual intercourse. The number of reported patients with ED is increasing and it is becoming a real medical problem.

Detailed description: Marital satisfaction is a global evaluation of the state of one's marriage or current long-term romantic relationship. This global evaluation can be a reflection of a how happy people are in their marriage in general or a composite of satisfaction with several specific facets of the marital relationship. Sexual health can be described as enjoying and fulfilling sexual desires without harming, physical or psychological, oneself or others. Sexual functioning is an important part of a patient's health and well-being. Patients often seek for treatment late due to embarrassment and commonly with an alternative problem. Sexual and erectile functions are considered important components of men's overall health. The psychosocial impact of ED can lead to depression, loss of self-esteem, and relationship and marital difficulties. Personality is defined as the "distinctive and characteristic patterns of thought, emotion and behavior that define an individual's personal style and influence his or her interaction with the environment".

Eligibility criteria: Inclusion Criteria:

* Married couples

Exclusion Criteria:

* Unmarried couples.

Primary outcomes:
measure: Marital and sexual satisfaction.
timeFrame: Six months.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04982120: Use of Repris Needle in Bladder Injection
Official title: A Post-510(k) Study of Patients With Overactive Bladder (OAB) Treated With OnabotulinumtoxinA (Botox, Allergan PLC) Using the Repris Bladder Injection System
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Overactive Bladder Syndrome
Lead sponsor: Uro-1 Medical
Sponsor class: INDUSTRY
First posted: 2021-07-29
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Treatment of overactive bladder (OAB) has been treated successfully by the injection of Botox. The Repris injection needle has a deflection that may assist in injection difficult to reach with standard straight needles. This study will assess the success, safety and patient tolerance of this new injection needle.

Detailed description: This is a prospective, multicenter, single arm study of the Repris injection needle to administer Botox to the bladder wall in patients with an overactive bladder. Following advancement of a cystoscope to the patient's bladder, the Repris needle will be advanced to the area of interest and into the bladder wall in order to administer the recommended volume of Botox. After injection, the needle will be removed and the procedure will be concluded. The patient will be asked to rank her tolerance of the procedure and level of discomfort using a standardized pain scale before being released. Five days after the procedure the patient will be contacted by telephone to determine whether any adverse events had occurred since release.

Eligibility criteria: Inclusion Criteria:

* Adult (18 years of age or older)
* Able to undergo routine cystoscopy
* Willing to provide verbal assessment of her condition within 5 days after the procedure

Exclusion Criteria:

* History of urethral strictures
* Presence of a suprapubic catheter or tube due to urethral trauma
* history of interstitial cystitis
* currently being treated for a urinary tract infection (UTI)
* gross hematuria present
* Known allergy or sensitivity to any component of the medication or solution to be injected during the study
* is pregnant, lactating, or with child-bearing potential unable or unwilling to use a reliable form of contraception while participating in the study
* cannot empty her bladder on her own and is routinely catheterizing the urethra
* unable to read, understand, and/or provide a ranking of pain level during the procedure,
* unable or unwilling to provide consent

Primary outcomes:
measure: Procedure Success
timeFrame: 1 Day of the procedure
Secondary outcomes:
measure: Patient Tolerance of Injection
timeFrame: 1 Day of the procedure
measure: Adverse Events during Procedure
timeFrame: Day 0 and Day 5
Other outcomes:
Locations:
city: Cartersville
country: United States
facility: Georgia Urology
state: Georgia
Study officials:
affiliation: Uro-1 Medical
name: Thomas Lawson, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00670020: Supplemental Perioperative Oxygen to Reduce the Incidence of Post-Cesarean Endometritis and Wound Infection
Official title: Supplemental Perioperative Oxygen to Reduce the Incidence of Post-Cesarean Endometritis and Wound Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Wound Infection or Endometritis Post Cesarean Section
Keywords: Women undergoing Cesarean section after the onset of labor
Lead sponsor: University of Washington
Sponsor class: OTHER
First posted: 2008-05-01
Enrollment: 143
Sex: FEMALE
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether supplemental perioperative oxygen significantly decreases the incidence of post-Cesarean endometritis and wound infection among women who undergo Cesarean section after the onset of labor.

Detailed description: Women undergoing cesarean section after rupture of membranes or onset of labor are randomized in a one to one ratio to either normal or supplemental perioperative oxygen during cesarean section and for two hours afterwards.

Eligibility criteria: Inclusion Criteria:

* Women who underwent a clinically indicated cesarean delivery after the onset of labor or rupture of membranes

Exclusion Criteria:

* Cesarean delivery prior to the onset of labor or rupture of membranes
* emergent cesarean delivery
* general endotracheal anesthesia
* clinical chorioamnionitis
* HIV infection
* less than 16 years of age

Primary outcomes:
measure: surgical site infection
timeFrame: within two weeks of cesarean section
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Washington Dept of Ob/Gyn
name: Carolyn M Gardella, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06967220: The Impact of Inflammation on Skeletal Muscle Maintenance in Hospitalized Patients
Official title: The Impact of Inflammation on Skeletal Muscle Maintenance in Hospitalized Patients
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Disease Related Malnutrition
High Systemic Inflammation
Geriatric Assessment
Lead sponsor: Bispebjerg Hospital
Sponsor class: OTHER
First posted: 2025-05-13
Enrollment: 90
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The main goal is to elucidate the mechanistic coupling between inflammation and the ability to maintain skeletal muscle through physical exercise while hospitalized. We will investigate protein kinetics in patients who belong to one of three groups 1) high inflammatory state, 2) moderate inflammatory state and 3) low/no inflammation. We will further intervene in group 1 (high inflammatory state) with anti-inflammatory nutrition (primarily green-solution plant-based) to diminish activity in inflammatory pathways. The hypothesis is that inflammation will inhibit protein synthesis in skeletal muscle both in resting muscle and in strength trained skeletal musculature, and that a lowering of the inflammatory status by anti-inflammatory nutrition will enhance the exercise induced formation of new muscle mass. .


Eligibility criteria: Inclusion Criteria:

* Hospitalised at the geriatric department at Bispebjerg Hospital with an expected admission time of minimum 7 days
* Have Disease Related Malnutrition (DRM)
* Able to carry out strength training
* Able to understand the study information, as assessed by the research team

Exclusion Criteria:

* Current use of anti-inflammatory medication
* Liver failure
* Short bowel syndrome
* Chrohn's or colitis
* Terminally ill

Primary outcomes:
measure: FSR in high vs. low inflammation group
timeFrame: 7 days (or until hospital discharge)
Secondary outcomes:
measure: Change in muscle size between groups
timeFrame: 7 days (or until hospital discharge)
measure: FSR in trained vs. non trained leg
timeFrame: 7 days (or until hospital discharge)
measure: Inflammation in regular vs. antiinflammatory diet
timeFrame: 7 days (or until hospital discharge)
measure: AA uptake following feeding
timeFrame: 7 days (or until hospital discharge)
measure: Muscle size in trained vs. untrained leg
timeFrame: 7 days (or until hospital discharge)
measure: Change in muscle strength between groups
timeFrame: 7 days (or until discharge)
measure: Muscle strength in trained vs. untrained leg
timeFrame: 7 days (or until hospital discharge)
Other outcomes:
measure: Feasibility of training
timeFrame: 7 days (or until hospital discharge)
Locations:
city: Copenhagen
country: Denmark
facility: Bispebjerg Hospital
Study officials:
References:
Clinical trial NCT04538820: Dexamethasone Dose for Postoperative Nausea and Vomiting Prophylaxis in Obese Patients
Official title: Dexamethasone Dose for Postoperative Nausea and Vomiting Prophylaxis in Obese Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Postoperative Nausea and Vomiting
Lead sponsor: Diskapi Yildirim Beyazit Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2020-09-04
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: compare the effectiveness of different doses of dexamethasone used for postoperative nausea and vomiting prophylaxis in obese patients and in normal weight patients.

Detailed description: compare the effectiveness of different doses of dexamethasone used for postoperative nausea and vomiting prophylaxis in obese patients.

compare the effectiveness of dexamethasone given in 4 mg and 8 mg doses in obese patients with 4 mg doses of dexamethasone in normal weight patients.

4 mg iv dexamethasone will be administered to normal weight patients at induction of anesthesia. This group will be classified as the control group. In obese patients (BMI\>30 kg/m2), one group will receive 4 mg dexamethasone and other group will receive 8 mg dexamethasone at induction.

Patients will receive general anesthesia with volatile anesthetics and tramadol will be administered IV at the end of surgery.

Postoperative nausea and vomiting, postoperative pain, blood glucose, wound infection, time to oral intake, hospital stay will be compared.

Eligibility criteria: Inclusion Criteria:

High risk patients for postoperative nausea and vomiting:

* Female
* No smoking
* BMI =18.5-24.9 for control group
* BMI \>30 for other groups
* undergo laparoscopic cholecystectomy

Exclusion Criteria:

* Diabetes mellitus

Primary outcomes:
measure: postoperative nausea and vomiting (PONV)
timeFrame: PONV scores wİll be record during the ﬁrst 24 hours
Secondary outcomes:
measure: postoperative pain: 11-point VRS
timeFrame: Pain will be assessed during the ﬁrst 24 hours
measure: oral intake
timeFrame: during the ﬁrst 24 hours
measure: blood glucose
timeFrame: at 6 and 10 hours after administration of dexamethasone
measure: Length of Hospital Stay
timeFrame: during the ﬁrst 24 hours
measure: wound infection
timeFrame: postoperative 30th day
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: DiskapiYBERH
Study officials:
References:
Clinical trial NCT02755220: Cingularbio® Heart Valve Clincial Study
Official title: A Prospective, Mutli-center, Open Lable, Single Arm Study to Evaluate the Safety and Effectiveness of Cingularbio® Heart Valve in Aortic/Mitral Valve Replacement Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diseases of Mitral and Aortic Valves
Lead sponsor: Shanghai Cingularbio Co. Ltd
Sponsor class: INDUSTRY
First posted: 2016-04-28
Enrollment: 197
Sex: ALL
Minimum age (years): 60
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aimed to evaluate the safety and effectiveness of Cingularbio® heart valve in Aortic Valve Replacement and Mitral Valve Replacement in Chinese population

Detailed description: single arm, 12 month follow up, mutile center, to assess the safety and effectiveness of Cingularbio® heart valve in Aortic Valve Replacement and Mitral Valve Replacement patients

Eligibility criteria: The inclusion criteria were as follows: 1) patient who had heart valve disease requiring a surgical replacement as indicated in the preoperative evaluation; 2) patient aged between 60-85 years; 3) patient whose preoperative heart function less than NYHA functional class IV; 4) patient who signed the informed consent before surgery; 5) patient who agrees to finish the follow-up. The exclusion criteria were as follows: 1) patient with prior valve replacement; 2) patient who requires concomitant tricuspid or pulmonary valve replacement; 3) patient who requires concomitant coronary artery bypass graft surgery; 4) patient with active infective endocarditis or drug abuse; 5) patient whose life time expectancy less than 12 months; 6) patient who was unable to follow anticoagulation treatment.

Primary outcomes:
measure: device related adverse valve events
timeFrame: 12 month
Secondary outcomes:
measure: rate of procedural success
timeFrame: post-operative
measure: the difference between baseline and 1 year in Effective orifice area (EOA)
timeFrame: 1year
measure: the difference between baseline and 1 year in pressure gradient (PG)
timeFrame: 1year
measure: the difference between baseline and 1 year in Peak aortic valve velocity
timeFrame: 1year
measure: improvement in NYHA functional class
timeFrame: 1year
measure: mortality
timeFrame: 1 year
measure: structural valve deterioration
timeFrame: 1 year
measure: reoperation
timeFrame: 1 year
measure: valve-related adverse events
timeFrame: 1 year
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: Cardiale Heelkunde
city: Shanghai
country: China
facility: Zhongshan Hospital of Fudan University
state: Shanghai
city: Katowice
country: Poland
facility: Klinika Kardiochirurgii
city: Kraków
country: Poland
facility: Klinika Kardiochirurgii
city: Warszawa
country: Poland
facility: Klinika Kardiochirurgii
Study officials:
affiliation: Fudan University
name: chunsheng wang
role: PRINCIPAL_INVESTIGATOR
References: